Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)

Inclusion Criteria

• •Patients with metastatic cancer
• •Patients may have received unlimited lines of prior therapy
• •Prior to randomization, patients with metastatic disease must have been treated with established standard-of-care therapy, or physicians have determined that such established therapy is not sufficiently efficacious, or patients have declined to receive standard-of-care therapy
• •The patient has measurable disease
• •The patient has Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• •The patient has biopsy-accessible tumor; for patients who had no prior anticancer therapy and had surgical resection within a year and tumor tissue is immediately available, that tumor will be analyzed and no biopsy will be needed
• •Absolute neutrophil count \>= 1,000/ul
• •Platelets \>= 100,000/ul (unless these abnormalities are due to bone marrow involvement)
• •Total bilirubin level \<= 1.5 x the upper limit of normal (ULN), unless the patient has known Gilbert's disease
• •Alanine aminotransferase (ALT)/ serum glutamic pyruvic transaminase levels (SGPT) =\< 2.5 X ULN (unless the patient has liver metastases)
• •Serum creatinine clearance \>= 50 ml/min by the Cockcroft-Gault formula
• •If the patient has brain metastasis, they must have been stable (treated and/or asymptomatic) and the patient must have been off steroids for at least 2 weeks
• •The patient has provided signed informed consent
• •Patients with a previous malignancy (other than the patients' known cancer) that were treated successfully and are disease-free for at least 3 years are allowed
• •Patients with a history of basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix are eligible
• •Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; childbearing potential will be defined as women who have had menses within the past 12 months and who have not had a tubal ligation, hysterectomy, or bilateral oophorectomy; should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately
• •Male subjects must agree to use effective contraception or abstinence while on study and for 90 days after last dose of study drug